Statins
Failure in drug safety assessment: a worrying issue far beyond manufacturer’s potential conflicts of interest
Tuesday 21 December 2004
by
In a 20-year old communication, I asked whether post-marketing surveillance was “an art or a science”: no doubt, twenty years later, that drug monitoring is just playacting, which may evolve in tragedies. Analysis of the statin story (amongst others) comes to the sad conclusion that regulatory bodies are currently unable to guarantee the protection of public health as far as a fair assessment of drugs benefit/risk ratios.
Marc Girard
Articles by this author
- P.C. Gøtzsche - La panique générale autour du coronavirus n’est pas justifiée (traduction)
- Les perles du coronavirus, du confinement, et (toujours) de la presse
- La CGT appelle à manifester contre la maladie de Lyme…
- Auditer les experts
- Élargissement des obligations vaccinales: mystérieuse épidémie chez les lanceurs d’alerte
- [...]
Keywords
-
Benefit/risk
- Vaccination contre l’hépatite B : essai de bilan chiffré
- Vaccin contre l’hépatite B : l’urgence d’une ré-évaluation
- Failure in drug safety assessment: a worrying issue far beyond manufacturer’s potential conflicts of interest
- Evaluation des statines
- Hepatitis B universal vaccination: learning from the French experience
- Conflict of interest
Home |
Contact |
Site Map
| Log in |
Site statistics |
Visitors :
5049 /
1531590
en Documents in English Statins ?